Arteriocyte is now a part of Isto Biologics.

News + Views


ISTO Technologies to Present at 2014 Stifel Healthcare Conference

Nov 11, 2014

November 11, 2014 (St. Louis, MO) – ISTO Technologies, Inc., a privately-held regenerative medicine company, announced that George Dunbar, the Company’s President and Chief Executive Officer, will present at the 2014 Stifel Healthcare Conference, as follows:

Event: 2014 Stifel Healthcare Conference
Date: November 18, 2014
Time: 4:10 pm EST
Location: The New York Palace Hotel (New York, NY) in The Winslow Room

About ISTO Technologies, Inc.
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. The Company’s proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. In addition to cell-based cartilage products in clinical development, ISTO manufactures and markets InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 30,000 surgeries at U.S. hospitals to date. For additional information on ISTO, please visit our website at

To top